BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 15892165)

  • 1. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
    Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H
    J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.
    Dorssers LC; van Agthoven T; Brinkman A; Veldscholte J; Smid M; Dechering KJ
    Breast Cancer Res; 2005; 7(1):R82-92. PubMed ID: 15642172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
    Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
    Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
    Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
    Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development.
    Zhang D; Schwarz EM; Rosier RN; Zuscik MJ; Puzas JE; O'Keefe RJ
    J Bone Miner Res; 2003 Sep; 18(9):1593-604. PubMed ID: 12968668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone morphogenetic proteins and growth and differentiation factors in the human cornea.
    You L; Kruse FE; Pohl J; Völcker HE
    Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):296-311. PubMed ID: 9950587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
    Ye L; Lewis-Russell JM; Davies G; Sanders AJ; Kynaston H; Jiang WG
    Int J Oncol; 2007 Feb; 30(2):521-9. PubMed ID: 17203235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells.
    Bokobza SM; Ye L; Kynaston HE; Mansel RE; Jiang WG
    Cancer Genomics Proteomics; 2009; 6(2):101-8. PubMed ID: 19451094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of potential Stat3-regulated genes in human breast cancer.
    Hsieh FC; Cheng G; Lin J
    Biochem Biophys Res Commun; 2005 Sep; 335(2):292-9. PubMed ID: 16081048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the distribution and clustering of the type I A BMP receptor (ALK3) with the type II BMP receptor on the activation of signalling pathways.
    Nohe A; Keating E; Underhill TM; Knaus P; Petersen NO
    J Cell Sci; 2003 Aug; 116(Pt 16):3277-84. PubMed ID: 12829744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moesin expression is associated with the estrogen receptor-negative breast cancer phenotype.
    Carmeci C; Thompson DA; Kuang WW; Lightdale N; Furthmayr H; Weigel RJ
    Surgery; 1998 Aug; 124(2):211-7. PubMed ID: 9706140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional interaction of fibroblast growth factor-8, bone morphogenetic protein and estrogen receptor in breast cancer cell proliferation.
    Masuda H; Otsuka F; Matsumoto Y; Takano M; Miyoshi T; Inagaki K; Shien T; Taira N; Makino H; Doihara H
    Mol Cell Endocrinol; 2011 Aug; 343(1-2):7-17. PubMed ID: 21664418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications.
    Badve S; Nakshatri H
    J Clin Pathol; 2009 Jan; 62(1):6-12. PubMed ID: 18794199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
    Zhang H; Stephens LC; Kumar R
    Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.
    Kurebayashi J; Otsuki T; Kunisue H; Tanaka K; Yamamoto S; Sonoo H
    Clin Cancer Res; 2000 Feb; 6(2):512-8. PubMed ID: 10690532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
    Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
    J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
    Ye L; Kynaston H; Jiang WG
    Mol Cancer Res; 2008 Oct; 6(10):1594-606. PubMed ID: 18922975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells.
    Pouliot F; Blais A; Labrie C
    Cancer Res; 2003 Jan; 63(2):277-81. PubMed ID: 12543773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.
    Licznerska BE; Wegman PP; Nordenskjöld B; Wingren S
    Breast Cancer Res Treat; 2008 Nov; 112(1):15-23. PubMed ID: 18030614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.